ZURA · XBRL financial data

Zura Bio financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZURA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	—	—	43,999	24,401	42,082
General and administrative	—	2,294	18,639	30,788	33,164
Total operating expenses	—	—	62,638	55,189	75,246
Operating income (loss)	—	(2,675)	(62,638)	(55,189)	(75,246)
Interest income	—	1	2,186	7,998	6,336
Other income (expense)	—	—	2,075	—	—
Income tax expense (benefit)	—	—	0	0	—
Net income (loss)	—	3,549	(60,360)	(52,403)	(68,650)
Earnings per share, basic USD per share	—	—	(2.09)	(0.60)	(1.06)
Earnings per share, diluted USD per share	—	—	(2.09)	(0.60)	(1.06)
Weighted average shares, basic thousands of shares	—	—	33,064	75,071	94,160
Weighted average shares, diluted thousands of shares	—	—	33,064	75,071	94,160

Fiscal years (ZURA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	729	14	99,800	176,498	109,407
Prepaid and other current assets	—	—	1,037	2,246	2,903
Total current assets	1,152	33	100,843	178,744	112,310
Property and equipment, net	—	—	—	91	126
Total assets	140,551	141,508	100,843	179,533	113,948
Accounts payable	70	282	2,749	733	1,279
Accrued liabilities	200	1,112	—	—	—
Total current liabilities	272	1,828	20,302	19,514	12,410
Total liabilities	10,352	7,760	21,292	19,514	12,410
Accumulated deficit	(9,181)	(7,627)	(103,494)	(155,897)	(224,547)
Total stockholders' equity	(9,181)	(7,626)	59,330	146,815	101,538
Total liabilities and equity	140,551	141,508	100,843	179,533	113,948
Common shares outstanding (cover page) thousands of shares	—	5,139	43,594	68,375	94,881

Fiscal years (ZURA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	3,549	(60,360)	(52,403)	(68,650)
Stock-based compensation	—	—	7,469	16,798	12,332
Depreciation and amortization	—	—	—	9	49
Net cash from operating activities	—	(1,071)	(15,054)	(28,076)	(64,815)
Purchases of property and equipment	—	—	—	75	113
Net cash from investing activities	—	—	(8,000)	(5,075)	(113)
Proceeds from issuing common stock	—	—	56,683	—	—
Net cash from financing activities	—	356	121,293	109,843	(2,163)
Net change in cash	—	(715)	—	—	—

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Zura Bio	187,652	not reported	(19)*	96.3M	9478.3 quarters	Q3 FY26 10-QSep 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Avalo Therapeutics	64,988	not reported	(11,541)*	57.8M	23.9 quarters	Q3 FY26 10-QSep 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 10:08 PM ET. The filing on SEC.gov is the record.